CYAN Cyanotech Corp.
Cyanotech Corp. engages in the development and commercialization of natural products derived from microalgae. Its products include BioAstin natural astaxanthin, a dietary antioxidant shown to support and maintain the body's natural inflammatory response, to enhance skin, and to support eye and joint health; and Spirulina Pacifica, a dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.
Company profile
Ticker
CYAN
Exchange
Website
CEO
Gerald R. Cysewski
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
SEC CIK
Corporate docs
IRS number
911206026
CYAN stock data
()
Investment data
Securities sold
Number of investors
Calendar
12 Nov 19
13 Dec 19
31 Mar 20
News
Company financial data Financial data
| Quarter (USD) | Sep 19 | Jun 19 | Mar 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | 7.69M | 8.07M | 6.06M | 10.04M | |
| Net income | 228K | -133K | -1.47M | 288K | |
| Diluted EPS | 0.04 | -0.02 | -0.25 | 0.05 | |
| Net profit margin | 2.96% | -1.65% | -24.31% | 2.87% | |
| Operating income | 409K | 49K | -1.32M | 495K | |
| Net change in cash | 39K | 115K | -633K | 910K | |
| Cash on hand | 1.09M | 1.06M | 940K | 1.57M | |
| Cost of revenue | 4.63M | 4.4M | 3.83M | 5.93M |
| Annual (USD) | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|
| Revenue | 30.2M | 34.12M | 32.04M | 31.84M | |
| Net income | -3.6M | 1.03M | -1.22M | -4.4M | |
| Diluted EPS | -0.62 | 0.18 | -0.21 | -0.79 | |
| Net profit margin | -11.91% | 3.00% | -3.79% | -13.80% | |
| Operating income | -3M | 1.41M | -682K | -785K | |
| Net change in cash | -389K | -78K | 167K | -986K | |
| Cash on hand | 940K | 1.33M | 1.41M | 1.24M | |
| Cost of revenue | 19.74M | 20.74M | 19.82M | 19.97M |
Financial data from Cyanotech earnings reports
Financial report summary
?Competition
CardaxManagement Discussion
- Net Sales Net sales decreased 11.5% in the year ended March 31, 2019 compared with 2018. This decrease was driven by a 9.2% decrease in sales of our packaged Nutrex Hawaii products, and a 30.2% decrease in bulk sales when compared with 2018. The decrease in packaged sales for spirulina was the result of lack of available product, which also impacted astaxanthin sales for certain channels that have historically displayed and promoted the two products together. The bulk sales decrease is also primarily the result of lack of product available for our bulk customers. Two customers accounted for 33% and 24%, respectively, of our total net sales in the fiscal year ended March 31, 2019. These two customers accounted for 32% and 15%, respectively, of our total net sales in the fiscal year ended March 31, 2018.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
al, behalf, breached, case, complaint, Court, declaratory, defendant, District, excessive, fiduciary, injunctive, LP, magnitude, Meridian, nominal, OHC, overseeing, proceed, relief, seeking, shareholder, slight
Removed:
arise, employment, Global, individually, intellectual, legal, ordinary, Select
Financial reports
10-Q
2020 Q2
Quarterly report
12 Nov 19
10-Q
2020 Q1
Quarterly report
13 Aug 19
10-K
2019 FY
Annual report
1 Jul 19
10-Q
2019 Q3
Quarterly report
13 Feb 19
10-Q
2019 Q2
Quarterly report
13 Nov 18
10-Q
2019 Q1
Quarterly report
13 Aug 18
10-K/A
2018 FY
Annual report (amended)
21 Jun 18
10-K
2018 FY
Annual report
15 Jun 18
10-Q
2018 Q3
Quarterly report
6 Feb 18
10-Q
2018 Q2
Quarterly report
6 Nov 17
Current reports
8-K
Submission of Matters to a Vote of Security Holders
27 Aug 19
8-K
Entry into a Material Definitive Agreement
7 Jun 19
8-K
Departure of Directors or Certain Officers
26 Apr 19
8-K
Entry into a Material Definitive Agreement
12 Apr 19
8-K
Cyanotech Names Brian Orlopp as VP Finance & Chief Financial Officer
9 Jan 19
8-K
Entry into a Material Definitive Agreement
7 Dec 18
8-K
Departure of Directors or Certain Officers
6 Nov 18
8-K
Other Events
7 Sep 18
8-K
Submission of Matters to a Vote of Security Holders
29 Aug 18
8-K
Other Events
13 Apr 18
Registration and prospectus
S-8
Registration of securities for employees
10 Nov 16
D
$378.98K in equity, sold $378.98K, 1 investor
10 May 16
S-8
Registration of securities for employees
17 Sep 14
S-8
Registration of securities for employees
21 Feb 12
S-8
Registration of securities for employees
10 Oct 08
S-8
Registration of securities for employees
5 Apr 07
S-8
Registration of securities for employees
5 Apr 07
S-3
Shelf registration
22 Nov 02
REGDEX
Notice of sale of securities
25 Oct 02
S-3/A
Shelf registration (amended)
10 Aug 00
Proxies
DEF 14A
Definitive proxy
10 Jul 19
DEF 14A
Definitive proxy
9 Jul 18
DEF 14A
Definitive proxy
7 Jul 17
DEF 14A
Definitive proxy
4 Nov 16
DEF 14A
Definitive proxy
15 Jul 16
DEF 14A
Definitive proxy
2 Sep 15
DEF 14A
Definitive proxy
18 Jul 14
DEF 14A
Definitive proxy
19 Jul 13
DEF 14A
Definitive proxy
18 Jul 12
DEFR14A
Revised proxy
21 Feb 12
Ownership
SC 13D/A
Beneficial ownership report (amended)
13 Mar 19
SC 13D/A
Beneficial ownership report (amended)
27 Feb 19
SC 13G/A
Cyanotech Corp
22 Jan 19
SC 13D/A
Beneficial ownership report (amended)
8 Nov 18
SC 13D/A
Beneficial ownership report (amended)
6 Nov 18
SC 13D/A
Beneficial ownership report (amended)
31 Oct 18
SC 13D
Beneficial ownership report
29 Oct 18
SC 13D/A
Beneficial ownership report (amended)
19 Oct 18
SC 13D
Beneficial ownership report
14 Feb 18
SC 13G/A
Cyanotech Corp
29 Jan 18